| Literature DB >> 29145843 |
Jiao Liu1,2, Yu Wang1,2, Yujiao Lu1,2, Ping Zheng3,4, Jibin Sun5,6, Yanhe Ma2.
Abstract
BACKGROUND: Corynebacterium glutamicum is an important industrial workhorse and advanced genetic engineering tools are urgently demanded. Recently, the clustered regularly interspaced short palindromic repeats (CRISPR) and their CRISPR-associated proteins (Cas) have revolutionized the field of genome engineering. The CRISPR/Cas9 system that utilizes NGG as protospacer adjacent motif (PAM) and has good targeting specificity can be developed into a powerful tool for efficient and precise genome editing of C. glutamicum.Entities:
Keywords: CRISPR/Cas9; Corynebacterium glutamicum; Double-locus editing; Gene deletion/insertion; Genome editing; Plasmid-borne templates; Single-nucleotide editing
Mesh:
Year: 2017 PMID: 29145843 PMCID: PMC5693361 DOI: 10.1186/s12934-017-0815-5
Source DB: PubMed Journal: Microb Cell Fact ISSN: 1475-2859 Impact factor: 5.328
Fig. 1Optimization of CRISPR/Cas9 system in C. glutamicum. a Schematic representation of the plasmids used for optimizing the promoter of Cas9 expression. The cas9 180bp-rfp fusion gene that consisted of the first 180 bp of cas9 gene and the full-length rfp gene was inserted into pXMJ19 under the control of IPTG-inducible promoter P (pRfp1) or propionate-inducible promoter P (pRfp2). The empty plasmid pXMJ19 was used as a negative control. b Optimization of promoters for Cas9 expression. pRfp1, pRfp2, and pXMJ19 were transformed into C. glutamicum SL4 separately. The resultant transformants were cultivated in SGY medium with or without 1 mM IPTG (for pRfp1) or 1 g/L sodium propionate (for pRfp2). Cells of the stationary growth phase were used to detect their fluorescence outputs using a microplate reader (λ excitation = 560 nm, λ emission = 607 nm). c Schematic representation of the plasmids used for verifying the function of the terminator derived from S. pyogenes (T ). A rfp gene was inserted downstream the gRNA (pRfp3) and the modified gRNA with T deleted (pRfp4). The empty plasmid pEC-XK99E was used as a negative control. d Function verification of T in E. coli and C. glutamicum by detecting fluorescence outputs of strains harboring pRfp3, pRfp4, or pEC-XK99E. e The gRNA structure derived from plasmid pgRNA1. f The optimized gRNA structure derived from plasmid pgRNA2. g Escape rate of CRISPR/Cas9-based counter-selection using different gRNA expression plasmid. pgRNA1 and pgRNA2 were transformed into C. glutamicum SL4 (pCas9) separately. Correct transformants were cultivated, diluted and spread on SGY plates containing Km and Cm, with or without IPTG (1 mM). The escape rate of counter-selection was calculated by colony counting
Fig. 2Gene deletion using CRISPR/Cas9 and plasmid-borne editing template in C. glutamicum SL4. a Schematic representation of pCas9, pgRNA3, and gene deletion event. b Transformants harboring pCas9 and pgRNA3 on a SGY plate supplemented with Km, Cm, and IPTG (1 mM). pCas9 and pgRNA3 were co-transformed into strain SL4 simultaneously and cells were spread on SGY plates with Km, Cm, and IPTG (1 mM) immediately after recovery. Colonies marked in red cycles were the so-called abnormally large colonies. c Schematic representation of different patterns of pCas9 mutation. Gene deletion, cas9 gene was removed from pCas9. Nonsense mutation, a T465G mutation occurred, generating a stop codon (TAT to TAG) in cas9 gene. Insertional inactivation, a transposase encoding gene from E. coli was inserted into cas9 gene, which deactivated cas9. d Colony counting and editing efficiency calculation of C. glutamicum SL4. Colonies on SGY plates supplemented with Km, Cm, and IPTG (1 mM) were counted and verified using colony PCR. e PCR verification of ldhA deletion in C. glutamicum SL4 using the primer pair (ldhA-up and ldhA-down) shown in a. M, DNA marker; –, wild-type control; 1–8, eight small colonies. This displayed the result of Replicate 1 in c. The results of Replicate 2 and Replicate 3 were shown in Additional file 1: Figure S2
Fig. 3Gene insertion using CRISPR/Cas9 and plasmid-borne editing template in C. glutamicum SL4. a Schematic representation of pCas9, pgRNA4, and gene insertion event. b Colony counting and editing efficiency calculation of C. glutamicum SL4. pCas9 and pgRNA4 were co-transformed into C. glutamicum SL4 simultaneously and cells were spread on SGY plates supplemented with Km, Cm, and IPTG (1 mM) immediately after recovery. Colonies on the selective plates were counted and verified using colony PCR. c PCR verification of rfp insertion in C. glutamicum SL4 using the primer pair (rfp-up and ldhA-down) shown in a. M, DNA marker; –, wild-type control; 1–10, ten small colonies. This displayed the result of Replicate 1 in b. The results of Replicate 2 and Replicate 3 were shown in Additional file 1: Figure S4
Fig. 4ssDNA-directed recombineering using CRISPR/Cas9 and RecT in C. glutamicum SL4ΔldhA::rfp. a Schematic representation of pCas9 and pgRNA5 which were used for ssDNA-directed recombineering. b Operation scheme of ssDNA-directed recombineering using CRISPR/Cas9 and RecT for rfp deactivation. A 90mer ssDNA targeted to the lagging strand (rfp-off1, Additional file 1: Table S1) is designed to introduce two successive stop codons (highlighted in red) in rfp gene. PAM sequence of the gRNA is shaded grey. Plasmid pgRNA5 was first transformed into C. glutamicum SL4ΔldhA::rfp. The resultant strain SL4ΔldhA::rfp (pgRNA5) was cultivated in SGY medium supplemented with Km and sodium propionate to induce RecT expression. Electrocompetent cells were then prepared and transformed with pCas9 and ssDNA. After recovery, cells were spread on SGY plates supplemented with Km, Cm, and IPTG (1 mM) to induce Cas9 expression for counter-selection. Colonies were picked randomly and verified by measuring their fluorescence outputs. c Fluorescence output detection of candidate mutants of C. glutamicum SL4ΔldhA::rfp off1. –, wild-type C. glutamicum SL4 control; +, C. glutamicum SL4ΔldhA::rfp; 1–10, ten colonies. This displayed the result of Replicate 1. The results of Replicate 2 and Replicate 3 were shown in Additional file 1: Figure S6. d rfp gene sequencing of C. glutamicum SL4ΔldhA::rfp off1 mutants. Nucleotides in red box represents the two successive stop codons (TAG TAA) introduced by ssDNA-directed recombineering. e StrR phenotype test of C. glutamicum SL4 rpsL K43R mutants. Ten colonies were picked randomly from SGY plates supplemented with Km, Cm, and IPTG (1 mM) and patched onto SGY plates (Str−) and SGY plates supplemented with streptomycin (Str+). Seven out of ten colonies were StrR. f rpsL gene sequencing of C. glutamicum SL4 rpsL K43R mutants. Nucleotides in red box represents the mutated codon (AAG to CGC) introduced by ssDNA-directed recombineering
CRISPR/Cas9-mediated gene deletion and insertion in C. glutamicum wild-type strains
| Strain | Plasmids used | Deleted fragment size (bp) | Inserted fragment size (bp) | Homologous arm size (bp) | Efficiency |
|---|---|---|---|---|---|
| ATCC 13869 | pCas9 and pgRNA3 | 664 | 0 | ~ 1000 | 30.8% (4/13); 35.7% (5/14); 33.3% (2/6) |
| pCas9 and pgRNA4 | 664 | 781 | ~ 1000 | 28.6% (4/14) | |
| ATCC 13032 | pCas9 and pgRNA3 | 664 | 0 | ~ 1000 | 60.0% (9/15) |
| pCas9 and pgRNA8 | 664 | 0 | ~ 500 | 50.0% (2/4) | |
| pCas9 and pgRNA9 | 8083 | 0 | ~ 1000 | 40.0% (2/5) | |
| pCas9 and pgRNA4 | 664 | 781 | ~ 1000 | 62.5% (5/8) | |
| pCas9 and pgRNA10 | 0 | 3626 | ~ 1000 | 50.0% (4/8) |
Fig. 5Double-locus editing in in C. glutamicum. a Schematic representation of pCas9 and pgRNA7 which were used for ssDNA-directed recombineering. b Mutants verification by sequencing of rfp and rpsL genes. Plasmid pgRNA7 that simultaneously expressed two gRNAs targeting rfp and rpsL was first transformed into C. glutamicum ATCC 13032::rfp. The resultant strain was then induced to express RecT and co-transformed with pCas9 and two kinds of synthetic ssDNAs (10 μg rfp-off1 and 10 μg rpsL-K43R, Additional file 1: Table S1). After recovery, cells were spread on SGY plates supplemented with Km, Cm, and IPTG (0.01 mM) to induce Cas9 expression for counter-selection. Colonies were picked and verified by gene sequencing
Strains and plasmids used in this study
| Strain or plasmid | Descriptiona | Reference or source |
|---|---|---|
|
| ||
| DH5α | General cloning host | TaKaRa |
| MG1655 | Source of | Lab collection |
|
| ||
| ATCC 13869 | Wild-type strain | ATCC |
| ATCC 13032 | Wild-type strain | ATCC |
| ATCC 13032:: | ATCC 13032 derivative with insertion of a | Lab collection |
| SL4 | ATCC 13869 derivative with high electrotransformation efficiency | Lab collection |
| SL4 (pCas9) | SL4 derivative harboring pCas9 | This work |
| SL4Δ | SL4 derivative with | This work |
| SL4Δ | SL4 derivative with insertion of a | This work |
| SL4Δ | SL4Δ | This work |
| SL4Δ | SL4Δ | This work |
| SL4 (pgRNA6) | SL4 derivative harboring pgRNA6 | This work |
| SL4 | SL4 derivative with K43R mutation of | This work |
| SL4 (pcas9 + pgRNA1) | SL4 derivative harboring pcas9 and pgRNA1 | This work |
| SL4 (pcas9 + pgRNA2) | SL4 derivative harboring pcas9 and pgRNA2 | This work |
| ATCC 13869Δ | ATCC 13869 derivative with | This work |
| ATCC 13032Δ | ATCC 13032 derivative with | This work |
| ATCC 13032Δ | ATCC 13032 derivative with | This work |
| ATCC 13032:: | ATCC 13032 derivative with | This work |
| ATCC 13032:: | ATCC 13032:: | This work |
| ATCC 13032:: | ATCC 13032:: | This work |
| ATCC 13032:: | ATCC 13032:: | This work |
| Plasmid | ||
| pEC-XK99E | Expression vector of | [ |
| pXMJ19 | Expression vector of | [ |
| pRed_Cas9_recA_Δpoxb300 | Source of | [ |
| pEC-XK99E- | Source of | Lab collection |
| pCas9 | pXMJ19 derivative carrying | This work |
| pRfp1 | pXMJ19 derivative carrying | This work |
| pRfp2 | pXMJ19 derivative carrying | This work |
| pRfp3 | pEC-XK99E derivative carrying gRNA- | This work |
| pRfp4 | pEC-XK99E derivative carrying gRNA (with | This work |
| pgRNA1 | pEC-XK99E derivative carrying gRNA targeting | This work |
| pgRNA2 | pEC-XK99E derivative carrying gRNA targeting | This work |
| pgRNA3 | pgRNA2 derivative carrying homologous arms (~ 1 kb) for | This work |
| pgRNA4 | pgRNA3 derivative with a | This work |
| pgRNA5 | pgRNA2 derivative carrying gRNA targeting | This work |
| pgRNA6 | pgRNA5 derivative carrying gRNA targeting | This work |
| pgRNA7 | pgRNA5 derivative carrying two gRNAs targeting | This work |
| pgRNA8 | pgRNA3 derivative carrying homologous arms (~ 0.5 kb) for | This work |
| pgRNA9 | pgRNA3 derivative carrying homologous arms (~ 1 kb) for | This work |
| pgRNA10 | pgRNA3 derivative carrying homologous arms (~ 1 kb), | This work |
aKmR and CmR represent resistance to kanamycin and chloramphenicol, respectively